Johnson & Johnson halted development of JNJ‑95475939 after an interim analysis failed to meet the company’s efficacy bar, while Genmab shelved acasunlimab, a PD‑L1x4‑1BB bispecific. J&J acquired its candidate from Numab for $1.25 billion in 2024; the early stop converts that bet into a strategic setback. J&J said the therapy was well tolerated but lacked sufficient efficacy versus the established anti‑IL‑4/13 standard. Genmab’s decision follows partner BioNTech’s earlier portfolio pull. These discontinuations will shape competitive dynamics in inflammation and immuno‑oncology R&D.